Cooley M&A

JANUARY 25, 2023

Although there were 104 initial public offerings of biotechnology companies in 2021 that raised nearly $15 billion in funds, 2022 saw only 22 such IPOs collectively raising less than $2 billion. Let’s dig in.

M&A 40

M&A Mergers and Acquisitions Pharmaceutical Collaboration 40

M&A Leadership Council

JUNE 12, 2023

The risks of brand damage, customer churn, and substantial costs have brought this topic to the forefront in many recent M&A Leadership Council workshops. We also believe it is vital to engage third parties to obtain a security risk assessment. AS: An excellent example of a deal-stop finding is basic IT or security collaterals.

IT 52

IT M&A Insurance Securities 52

M&A Leadership Council

SEPTEMBER 9, 2021

The risks of brand damage, customer churn, and substantial costs have brought this topic to the forefront in many recent M&A Leadership Council workshops. We also believe it is vital to engage third parties to obtain a security risk assessment. AS: An excellent example of a deal-stop finding is basic IT or security collaterals.

IT 52

IT M&A Insurance Securities 52